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Abstract
Background: The main study objectives were: to establish a nationwide voluntary collaborative
network of breast centres with independent data analysis; to define suitable quality indicators (QIs)
for benchmarking the quality of breast cancer (BC) care; to demonstrate existing differences in BC
care quality; and to show that BC care quality improved with benchmarking from 2003 to 2007.
Methods: BC centres participated voluntarily in a scientific benchmarking procedure. A generic
XML-based data set was developed and used for data collection. Nine guideline-based quality
targets serving as rate-based QIs were initially defined, reviewed annually and modified or
expanded accordingly. QI changes over time were analysed descriptively.
Results:  During 2003–2007, respective increases in participating breast centres and
postoperatively confirmed BCs were from 59 to 220 and from 5,994 to 31,656 (> 60% of new BCs/
year in Germany). Starting from 9 process QIs, 12 QIs were developed by 2007 as surrogates for
long-term outcome. Results for most QIs increased. From 2003 to 2007, the most notable
increases seen were for preoperative histological confirmation of diagnosis (58% (in 2003) to 88%
(in 2007)), appropriate endocrine therapy in hormone receptor-positive patients (27 to 93%),
appropriate radiotherapy after breast-conserving therapy (20 to 79%) and appropriate
radiotherapy after mastectomy (8 to 65%).
Conclusion:  Nationwide external benchmarking of BC care is feasible and successful. The
benchmarking system described allows both comparisons among participating institutions as well
as the tracking of changes in average quality of care over time for the network as a whole. Marked
QI increases indicate improved quality of BC care.
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Background
Implementing and maintaining quality assurance proce-
dures and improving cancer care are two key areas of
multidisciplinary oncology today. With the high inci-
dence of breast cancer (BC) and the recognised necessity
for a multidisciplinary approach to its treatment, the man-
agement of this cancer can be considered a prototypical
example of an entire process chain ranging from early
detection, diagnosis and treatment to follow-up.
Multidisciplinary and intersectoral, i.e. in- and out-
patient, BC care requires elements of quality manage-
ment, particularly at various interfaces along the process
chain. In addition, maintaining a quality management
system (QMS) with continual quality assurance (QA),
which includes both comprehensive documentation of all
treatments and external analysis of the QA data, is also
one of the prerequisites in Germany for the certification of
breast centres [1,2] in accordance with the Requirements
of Breast Centres (FAB) [3] set by the German Cancer Soci-
ety (DKG) and the German Society of Senology (DGS)
largely on the basis of two multidisciplinary level-3 guide-
lines [4,5].
To measure and improve the quality of care provided to
BC patients has also in recent years been the main objec-
tive of a collaboration established in 2003 between the
DGS, DKG and German Society of Obstetrics and Gynae-
cology (DGGG) on the one hand and the West German
Breast Centre (WBC), a subsidiary of the German Oncol-
ogy Centre (DOC), on the other. The mainstays of this
approach are the centralisation of expertise in certified
breast centres treating more than 150 primary breast can-
cer patients per year, and determination of the quality of
care at a national level by independent external documen-
tation and analysis of the relevant QA data [1,2,6].
Establishing a nationwide oncology benchmarking sys-
tem to achieve this goal, however, requires the creation of
a suitable infrastructure and appropriate procedures for
the collection of uniformly structured, preferably XML-
based QA data from the participating institutions and for
the analysis of such data. Based on clinical parameters
derived from the QA data, quality indicators (QIs) need to
be defined as measures of quality of care. To be suitable as
QIs, these measures need to reflect the FAB requirements
and the degree to which they are achieved by each partic-
ipating institution. The individual results for each QI can
then be used to rank centres (which are coded to protect
their reputation) and to determine current mean achieve-
ment of the relevant FAB requirements. In addition, mean
degrees of achievement of the requirements can be ana-
lysed over multi-year periods to determine longer-term
changes in QIs and thus in quality of care. In theory, QIs
can be defined for all three types of quality – process,
structural and outcome quality – but in practice bench-
marking of BC care must resort to process QIs as surro-
gates for outcome quality for at least the first five years.
Because of the well-known protracted natural history of
breast cancer, QIs representing outcome in terms of mor-
bidity and mortality, e.g. complication and relapse rates
and disease-free survival, can be anticipated to require a
minimum of five to ten years of data accrual.
The aim of the present study was to establish a compre-
hensive collaborative network based on voluntary self-
declaration of QA data which would ultimately encom-
pass all breast cancer centres in Germany and, eventually,
internationally; to develop suitable indicators for bench-
marking the quality of care delivered to BC patients, pri-
marily in Germany; and to demonstrate that the quality of
cancer care could be assessed, and subsequently
improved, by means of standardised collection and anal-
ysis of such voluntary QA data by an independent organ-
isation in accordance with the criteria specified by the
relevant medical societies.
To this end, the study sought to address a number of key
points, the first being to demonstrate in principle the fea-
sibility of voluntary self-declaration of QA data by breast
centres in Germany to ascertain the quality of BC care
resulting from the introduction of multidisciplinary
breast centres, particularly certified centres, and the
greater transparency of QA data associated with their
establishment. The next points to be verified were whether
such QA data could be centrally collected and analysed by
an independent external scientific organisation, whether
the data were plausible and what indicators of process
quality would be suitable as surrogates for outcome qual-
ity in order to provide proof of concept for uniform
benchmarking of BC care. The last point concerned the
extent to which the collection and logical analysis of QA
data could be harmonised and conducted homogene-
ously, and the question whether such a benchmarking sys-
tem of QIs would indeed reflect the expected continual
improvement in the care of breast cancer patients over the
first five-year period of the study.
In the following we aim to show on the basis of the data
from 2003 to 2007 that it proved possible in Germany to
establish a collaboration between a growing suprare-
gional voluntary network of breast centres and an inde-
pendent provider of external data collection and data
analysis services, that self-declaration yielded plausible,
uniform QA data, and that the newly implemented
benchmarking system proved a successful instrument for
quality assurance and indeed reflected improvement in
BC care during the study period.BMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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Methods
Study design and objectives
The present study was a prospective interventional multi-
centre feasibility study designed to provide proof of con-
cept that the quality of breast cancer (BC) care in Germany
could be measured scientifically and improved by imple-
menting a supraregional benchmarking system based on
a set quality indicators (QIs) derived from clinically rele-
vant parameters in accordance with criteria laid down by
the relevant scientific medical societies.
The study was prospective in that it was initiated to iden-
tify and calculate QIs from collected BC treatment data,
and to review and reassess the QIs annually with regard to
their suitability as indicators of quality, and of differences
in quality, of BC care, with the option of modifying exist-
ing QIs or adding new ones, or of abandoning any QIs
that lacked discriminatory power so as ultimately to dem-
onstrate in terms of QI increases the postulated improve-
ment in quality of care from benchmarking over a period
of several years.
The study was interventional in two respects. Firstly, a col-
laborative study network of BC centres needed to be estab-
lished at the outset to enable external collection of
structured data sets and to identify suitable QIs for bench-
marking quality of treatment and care. Secondly, it was
necessary for the purpose of external data collection and
independent data analysis to establish collaboration with
a provider of such services that was separate from, and
independent of, the participating clinical institutions. To
this end, a formal collaboration was established with the
West German Breast Centre (Westdeutsches Brust-Cen-
trum; WBC), a subsidiary of the German Oncology Centre
(Deutsches Onkologie Centrum; DOC), Düsseldorf, Ger-
many.
An additional focus was on developing an XML-based
data set structure that would be compatible with any type
of breast cancer documentation software and suitable for
cancer care quality assurance in order to enable, ensure
and enhance uniform data collection and data analysis.
The final objective of the study was to show that suprare-
gional collaborative benchmarking would be associated
with continual, marked improvement in the quality of
multidisciplinary BC care even during the first five-year
period from 2003 to 2007.
Participating institutions
Hospitals and specialist breast centres in Germany and
Switzerland (as of 2006) with a focus on BC care were
invited to participate on a voluntary basis in an external,
independent, scientific benchmarking system developed
by the German Cancer Society (DKG) and the German
Society of Senology (DGS) and operated by the WBC/
DOC (West German Breast Centre/German Oncology
Centre).
Data collection
Data collection was based on voluntary registration of BC
treatment institutions with the benchmarking system. For
each patient, the data for the 173 parameters from the
DKG/DGS Requirements of Breast Centres (FAB) and a
number of additional parameters were collected by staff
members of the participating institutions from 1 January,
2003 to 31 December, 2007. The data were initially
recorded using primarily the database-driven oncological
documentation system ODSeasy (asthenis®  GmbH,
Aschheim, Germany). Data collection later used a generic
XML-based data set (see below), as the XML technology
enables data to be collected from different types of docu-
mentation systems. Anonymised (coded) and encrypted
data sets were stored on CD-ROM and submitted to the
WBC/DOC for independent external analysis twice a year.
Quality indicators
The 173 individual parameters from the DKG/DGS
requirements (FAB) were grouped to yield clinically based
QIs designed to determine the degree of achievement of
predefined quality targets. The QIs were reviewed once a
year, at which time existing QIs were modified, or discon-
tinued if they lacked discriminatory power, and new indi-
cators or subindicators were added, as deemed
appropriate by the scientific advisory board.
Methodologically, the QIs used in our study were rate-
based indicators with a primary focus on the generally rec-
ognised necessity of process quality in terms of compli-
ance with treatment guidelines and methods of decision-
making. Process QIs (PQIs) served as short-term surro-
gate parameters for outcome quality, until the accrual of
sufficient data over period of 5 to 10 years would permit
calculation of long-term outcome QIs, the ultimate objec-
tive of the project as a whole.
Plausibility checks and monitoring
All data from the participating institutions were centrally
collected and analysed at the WBC/DOC, and the results
of the analysis were reported back twice a year. Data plau-
sibility was ensured by means of twice yearly monitoring
visits and data reviews at the annual participants' meet-
ings.
The primary purpose of the monitoring visits was to check
the electronic documentation extracted from patients'
medical records for correctness and completeness in order
to ensure that the database would be valid and suitable for
analysis according to the benchmarking procedure. In
addition, the monitoring visits were also intended asBMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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opportunities to discuss, and advise on, issues related to
the documentation process [7,8].
Generic XML-based data set
To eliminate problems associated with different tumour
documentation systems being used as the number of par-
ticipating institutions rose over the study period, it soon
became necessary to develop a generic XML-based data set
that would readily integrate with various software sys-
tems. In their role as the leading scientific organisations
for BC in Germany, the DKG (German Cancer Society)
and DGS (German Society of Senology) determined the
contents and calculation algorithms of the XML data set
on the basis of the level-3 guidelines on early detection of
breast cancer in Germany, the interdisciplinary S3 guide-
lines for the diagnosis and treatment of breast cancer in
women and the DKG/DGS Requirements of Breast Cen-
tres (FAB) [3,9,5].
To harmonise and standardise the clinical parameters and
validate software providers in the context of breast centre
certification to the DKG/DGS requirements, the WBC/
DOC (West German Breast Centre/German Oncology
Centre) was commissioned as an independent external
service provider to program a suitable XML-based data set
comprising the algorithms for calculation of the QIs.
The XML data set with the algorithms were integrated with
the participating institutions' various tumour documenta-
tion systems by the respective software providers to ensure
the availability of uniform documentation options and
QI calculations for the DKG/DGS questionnaire on all
computer systems and the implementation of nationwide
standards for data generation and data assessment. The
programming of the XML data set was overseen by the
DKG/DGS and the AGO (DGGG Working Group on
Gynaecological Oncology).
Data analysis and reporting
Data analysis was performed by the WBC/DOC with the
aid of standard software, including Access®, Excel® and
Word® from Microsoft Office 2002/2003 and Microsoft
SQL Server 2005 (Microsoft Corporation, Redmond, WA,
USA). The query logic was written in SQL and therefore
was also compatible with other software products.
For each participating institution and QI, the mean
annual percentage of all patients was calculated who were
diagnosed or treated in accordance with the relevant QI
requirements. For each QI, the participating institutions
were then ranked by calculated mean annual percentage,
and an overall mean annual percentage was calculated
across all participating institutions. In addition, 95% con-
fidence intervals were calculated, which are indicative of
the size of the underlying population.
Changes over time in the quality indicators were analysed
for the 2003–2007 period using descriptive numerical
and graphical methods (tables and histograms). No statis-
tical tests were employed.
The WBC/DOC (West German Breast Centre/German
Oncology Centre) provided the participating institutions
with six-monthly reports on their individual performance
in comparison with the other participants. Semi-annual
and annual overall reports in which all hospitals were
coded for anonymity were compiled, distributed within
the network and also made publicly available online at
http://www.brustcentrum.de.
Further details of the methodology are provided in the
WBC's annual reports for 2003 to 2007, which are availa-
ble online at http://www.brustcentrum.de (in German)
[7,8,10-12].
Results
Participating institutions, monitoring visits and case 
numbers
As of 2003, a growing number of hospitals and specialist
breast centres with a focus on BC care in Germany and, as
of 2006, Switzerland entered into formal collaboration
with the WBC/DOC (West German Breast Centre/German
Oncology Centre) to participate in the voluntary, external
and independent scientific benchmarking system oper-
ated by the WBC/DOC. This is illustrated by Figure 1,
which also shows the accompanying rise in the number of
visits per year (median 2.14, range 1.62–2.37) by specially
trained monitors to the participating institutions during
the 2003–2007 period.
The number of primary BC cases per year as confirmed by
postoperative histology also showed a steady increase dur-
ing the 2003–2007 period, as shown in Figure 2. This
marked, 5.28-fold increase in histologically confirmed
primary BC cases accompanied a 3,73-fold increase in the
number of participating institutions achieved during the
five-year study period, reflecting a steady rise in the
number of postoperatively confirmed primary BC cases
per participating institution from 101.59 in 2003 to 143.8
in 2007.
XML-based data set
A generic XML-based data set was successfully developed
that readily integrated with various types of tumour docu-
mentation software and enabled uniform data collection
and data analysis. The contents of the XML data set and
the embedded calculation algorithms were determined by
the DKG (German Cancer Society) and DGS (German
Society of Senology) on the basis of the DKG/DGS
Requirements of Breast Centres (FAB) [3] and thus wereBMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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essentially based on the two relevant level-3 guidelines
[9,5].
In addition to encompassing the 173 DKG/DGS Require-
ments of Breast Centres relevant to DKG/DGS certifica-
tion, the custom-designed, XML-based data set structure
also accommodated data relevant to EUSOMA (European
Society of Breast Cancer Specialists) certification of breast
centres [13] as well as additional items required by Ger-
man law.
The XML data set and the embedded algorithms were used
successfully to ensure uniform documentation and calcu-
lation of QIs and the implementation of nationwide
standards for data generation and data assessment.
Quality indicators (QIs)
Starting in 2003 from a set of 9 QIs (Nos. 1, 2, ex-3, 5, 6,
7.1 b, 9, 10 and 11 b in Table 1) derived from the clinical
parameters laid down in the DKG/DGS Requirements of
Breast Centres (FAB), QIs were reviewed once a year and
modified, expanded or discontinued on the advice of the
scientific advisory board. Table 1 shows the set of 12 QIs
and 9 subindicators used in 2007 to benchmark breast
cancer care, listing each QI with its year of introduction,
rationale and quality target and the relevant DKG/DGS
requirements for years 1 and 3 of the DKG/DGS certifica-
tion procedure. The QIs identified for the new, nation-
wide benchmarking system cover a number of crucial
aspects of the treatment chain process, ranging from pre-
operative (QI No. 1) and operative (Nos. 2–4) aspects to
breast conserving therapy (BCT) (No. 11), hormone
receptor assessment (No. 5) and endocrine therapy (No.
6), neoadjuvant and adjuvant chemotherapy as standard
regimens (Nos. 7.1 and 7.2) and study regimens (No. 8)
and radiotherapy after BCT or mastectomy (No. 9 and
10). In addition to these process-based surrogate QIs, the
rate of relapse-free survival (RFS) has now been identified
as the first true indicator of outcome quality to be imple-
mented. However, RFS data are not expected to be availa-
ble until 2009 at the earliest.
In the context of the present analysis, the DKG/DGS (Ger-
man Cancer Society/German Society of Senology)
requirements served as target values. No DKG/DGS
requirement applied strictly to QIs 7.1b, 11.a and 11.c-e,
as these were not restricted to age ≤  70 years. QIs Nos. 7.1b,
7.2a, 7.2b pertaining to the use of appropriate standard
regimens in chemotherapy were not directly derived from
the relevant level-3 guidelines but were introduced on the
advice of the scientific advisory board. The two QIs which
were abandoned at the end of 2006 and are designated
"ex-3" and "ex-4" in Table 1 have been included to illus-
trate how the benchmarking procedure provides for the
scientific advisory board to discontinue QIs no longer
considered to offer sufficient discriminatory power.
In an attempt to allow hospitals more time to complete
entry of e.g. adjuvant and neoadjuvant chemotherapy
data into their computer systems, previous-year QIs were
introduced in 2006 (not shown) [8]. The rationale of such
QIs was that they would contribute to a more complete
and accurate database and ultimately enhance the validity
of the analysis. However, these subindicators proved
unsatisfactory and were abandoned again in 2007.
Instead, a general 90-day lag was introduced to allow for
completion of data entry.
QI development during the 2003–2007 period
The results for all QIs evaluated in 2007 are summarised
in Table 2, which also shows how the indicators devel-
oped during the 2003–2007 period and exemplifies the
adaptability of the benchmarking system in terms of ena-
bling addition or discontinuation of QIs. In particular,
Table 2 illustrates the addition of new QIs from 2005 to
2007 and the replacement of Nos. "ex-3" and "ex-4" by
the new Nos. 3 and 4 in 2007.
Among the eight indicators tracked throughout the study
period from 2003 to 2007, Nos. 1, 6, 7.1b, 9 and 10
showed marked increases, while the others exhibited little
change (Nos.5 and 11a) or practically no (No. 2) change.
Among the seven indicators tracked for at least two years
during the study period, moderate increases were seen for
Nos. ex-3, 7.1a and 7.2b, while little change was noted in
Nos. ex-4, 7.2a and 11.b, and No. 8 remained practically
unchanged.
Number of breast centres participating in the benchmarking  of breast cancer care and number of monitoring visits during  2003–2007 Figure 1
Number of breast centres participating in the bench-
marking of breast cancer care and number of moni-
toring visits during 2003–2007.
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For those QIs representing parameters for which the DKG/
DGS Requirements of Breast Centres (FAB) specified tar-
get values, performance levels were calculated relative to
the third-year DKG/DGS certification requirements. These
were stricter than the first-year requirements in the cases
of QIs Nos. 2, 6, 7.1b, 8 and 11b. The resulting QI per-
formance data are shown in Figure 3. They clearly illus-
trate for most QIs how individual indicators developed
over the 2003–2007 period. For instance, the perform-
ance levels of QIs Nos. 1 (preoperative histology) and 6
(endocrine therapy in receptor-positive patients), were
low (58%) or very low (27%) in 2003, but improved to
high levels around 90% by 2007. Nos. 9 (radiotherapy
after BCT) and 10 (radiotherapy after mastectomy)
increased from very low levels (20% and 8%) to high
(79%) or intermediate (65%) levels, respectively. QIs
Nos. 2 (axillary dissection), ex-3 (complete tumour stag-
ing data), 5 (hormone receptor assessment) and 7.1a
(adjuvant and neoadjuvant chemotherapy at age ≤  70
years) had high initial levels and either remained essen-
tially unchanged at about the first-year DKG/DGS level
(No. 2) or improved further to achieve levels close to
(Nos. ex-3 (by 2006) and 5) or in excess of 100% (No.
7.1a). The relative performance of QI No. 11b (BCT at T1)
was consistently above 100% from 2005, the year of its
introduction, until 2007, as it always exceeded the DKG/
DGS requirement that BCT be recommended in at least
70% of patients with T1 tumours.
Discussion
Breast cancer continues to be the most common cancer in
women in Germany and throughout the world [14,15].
With more than 55,100 women estimated to be diag-
nosed with breast cancer annually, Germany ranked ninth
in a 2002 comparison of the incidence rates of BC in 24
European countries [15].
In recent years, health policies in Germany have under-
scored the increasing importance attributed to breast can-
cer [16,17]. Efforts have been directed towards developing
and implementing structured, intersectoral quality man-
agement programmes aimed at optimising breast cancer
care to reduce inappropriate care and the over- and under-
provision of care [18].
Until the initiation of the present study in 2003, however,
no suitable software, necessary infrastructure or bench-
marking system with specific collaboration agreements
existed either at the national or international level.
Moreover, despite the clear need for benchmarking sys-
tems to assess cancer care, literature searches conducted
up to 2007 yielded no evidence indicating that mandatory
or voluntary supraregional inter-institutional benchmark-
ing systems existed in other countries for collecting and
analysing data on the quality of care provided to patients
with breast cancer, or other cancers. This shows the nov-
elty of the approach that has been pursued in Germany
since 2003 with the aim of creating a national benchmark-
ing network of breast centres. To the best of our knowl-
edge this is the first publication in the international
literature to report on the implementation of, and present
initial data from, a comprehensive nationwide QA system
for benchmarking the quality of cancer care along the
entire process from diagnosis to follow-up.
The objectives of the present proof-of-concept study were
fourfold: 
1. to demonstrate the feasibility of QA in breast cancer
care by establishing a voluntary benchmarking network of
breast centres in collaboration with an external, inde-
pendent service provider commissioned to collect and
analyse the QA data;
2. to identify and define QIs based on clinical parameters
in accordance with the criteria laid down by the relevant
scientific medical societies;
3. to develop an XML data set designed to enable uniform
collection and analysis of the participants' QA data; and
finally,
4. to determine whether and to what extent such a bench-
marking system would be able to reveal QI-specific differ-
ences between the (anonymised) participating
institutions and to quantify the QI changes across the net-
work as a whole over the first five-year period from 2003
to 2007.
The marked year-to-year increases in breast centre partic-
ipation, the resulting 3.7-fold overall increase in partici-
Histologically confirmed primary breast cancers reported by  the participating institutions during 2003–2007 Figure 2
Histologically confirmed primary breast cancers 
reported by the participating institutions during 
2003–2007.
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Table 1: Quality indicators (QIs) used in the new, nationwide system for benchmarking breast cancer care in 2007
QI No. Quality indicator (QI) Introduced Based on Quality target DKG/DGS (FAB) requirement
1P r e o p e r a t i v e  
histological 
confirmation of 
diagnosis
2003 L3-GL/ED-BC 
(2003)
Frequent preoperative 
histological confirmation of 
diagnosis in invasive breast 
cancer
> 90% (palpable tumours), > 70% 
(nonpalpable tumours)
2 Appropriate axillary 
dissection
2003 L3-GL/DT-BC 
(2004)
Appropriate axillary 
dissection in all patients with 
invasive breast cancer 
(axillary clearance)
> 85% at initial certification; > 95% 
after 3 years
[ex-3]a Complete tumour staging 
data
2003 L3-GL/DT-BC 
(2004)
Complete information on 
tumour stage (T-N-M-R-G) for 
all patients
> 95% for pT and pN in invasive BC
3 Data on safety distance 
between tumour and 
resection margin
2007 L3-GL/DT-BC 
(2004)
Data on safety distance for all 
patients
Pathologist's report must state the 
resection margin and minimum 
safety distance in 100% of cases 
(exceptions require justification)
[ex-4]a HER-2/neu assessment 2005 Generally accepted 
criterion
Frequent assessment of HER-2/
neu status
> 95% in invasive BC
4 Specimen radiography 2007 Generally 
accepted criterion
Specimen radiography after 
preoperative wire 
localisation
Postoperative specimen radiography 
of microcalcifications following 
preoperative wire localisation in > 
95% of cases
5 Hormone receptor 
assessment
2003 L3-GL/DT-BC 
(2004)
Assessment of hormone 
receptor status in all patients
100% (except in justified cases)
6 Appropriate endocrine 
therapy in hormone 
receptor-positive 
patients
2003 L3-GL/DT-BC 
(2004)
Endocrine therapy in all 
hormone receptor-positive 
patients
> 70% at initial certification; > 95% 
after 3 years
7.1 Appropriate adjuvant 
and neoadjuvant 
chemotherapy
2003 L3-GL/DT-BC 
(2004)
Frequent appropriate 
adjuvant or neoadjuvant 
chemotherapy in breast 
cancer patients with negative 
hormone receptor status, or 
with ≥ 4 affected lymph 
nodes irrespective of 
receptor status
See 7.1a and 7.1b
7.1a during the current analysis 
period; age ≤  70 years
2005 L3-GL/DT-BC 
(2004)
See QI 7.1 > 70% at initial certification; > 80% 
after 3 years in patients ≤  70 years
7.1b during the current analysis 
period; no age limit
2003 L3-GL/DT-BC 
(2004)
See QI 7.1 n. d.
7.2 Use of appropriate 
standard regimens in 
chemotherapy
2005 n. d. Frequent use of appropriate 
standard regimens in 
chemotherapy
n. d.
7.2a during the current analysis 
period; age ≤  70 years
2006 n. d. See QI 7.2 n. d.
7.2b during the current analysis 
period; no age limit
2005 n. d. See QI 7.2 n. d.
8 Percentage of patients 
in clinical trials
2005 L3-GL/DT-BC 
(2004)
Frequent inclusion of patients 
in clinical trials
≥ 10% and ≥ 20% primary breast 
cancers at initial certification and 
after 3 years, respectivelyBMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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pating centres from 59 in 2003 to 220 by the end of 2007
and the associated rise in the number of annual external
monitoring visits shown in Figure 1 clearly demonstrate
that voluntary collection and analysis of QA data for
benchmarking the quality of breast cancer care based on
self-declaration rather than legislation was both feasible
and well accepted by the treatment centres. With a median
2.14 monitoring visits per year, the monitoring data were
also consistent with the planned number of 2 visits per
year.
The substantial, 5.28-fold increase in the number of his-
tologically confirmed primary breast cancers reported to
the WBC/DOC (West German Breast Centre/German
Oncology Centre) from 5,994 in 2003 to 31,656 in 2007
also clearly indicates the high level of acceptance among
the participating centres for the voluntary collection of
QA data for benchmarking and the success of the bench-
marking system as a whole. Whereas our benchmarking
system accounted for some 15% of breast cancer cases in
Germany in 2003, the more than 31,000 new cases of his-
tologically confirmed breast cancer reported in 2007 rep-
resent about 63% of the 50,100 new breast cancers
estimated to occur in Germany every year [10,8].
As regards annual caseload, it is worth noting that even in
the first year of the study the mean number of histologi-
cally confirmed primary breast cancers per participating
centre exceeded 100, the volume of new cases found by
Hébert-Croteau et al. to be associated with improved sur-
vival [19]. In fact, mean annual caseload per centre rose
consistently by 41.6% in the present study from 101.6 in
2003 to 143.9 by the end of 2007. This finding could sug-
gest that by the end of 2007, mean caseload was
approaching the high annual volume of 150 surgical cases
per hospital shown by Roohan et al. to be associated with
a significant positive effect on 5-year survival from breast
cancer [20]. A plausible interpretation of the observed
increases in mean caseload per centre is that they reflect a
trend towards centralisation in breast cancer care as a
result of the increasing referral of patients to specialist
breast centres over the study period, thus indirectly indi-
cating improvement in the quality of BC care.
Lastly, the cumulative number of data sets (postopera-
tively confirmed primary breast cancers) collected by 31
December, 2007 exceeded 92,000.
Taken together, these results provide clear evidence of the
willingness among breast centres in Germany, and more
recently Switzerland, to engage in self-declaration of QA
data relating to breast cancer care. They reflect the project's
remarkable success in implementing and maintaining a
network for benchmarking breast cancer care and there-
fore can be considered to provide proof of concept for the
feasibility of such a system.
9 Appropriate 
radiotherapy after 
breast-conserving 
therapy
2003 L3-GL/DT-BC 
(2004)
Appropriate radiotherapy for 
all patients receiving breast-
conserving therapy
Complete record of the number of 
radiation treatments; exceptions 
require justification
10 Appropriate 
radiotherapy after 
mastectomy
2003 L3-GL/DT-BC 
(2004)
Appropriate radiotherapy for 
all mastectomy patients
Complete record of the number of 
radiation treatments; exceptions 
require justification
11 Indication for breast-
conserving therapy
2003 L3-GL/DT-BC 
(2004)
Appropriate indication for 
breast-conserving therapy in 
all patients
Breast-conserving surgery for pT1 
tumours; > 50% at initial 
certification, > 70% after 3 years
11a at any tumour stage 2003 L3-GL/DT-BC 
(2004)
See QI 11 n. d.
11b at T1 2005 L3-GL/DT-BC 
(2004)
See QI 11 Breast-conserving surgery for pT1 
tumours; > 50% at initial 
certification, > 70% after 3 years
11c at T2 2006 L3-GL/DT-BC 
(2004)
See QI 11 n. d.
11d at T3 2006 L3-GL/DT-BC 
(2004)
See QI 11 n. d.
11e at T4 2006 L3-GL/DT-BC 
(2004)
See QI 11 n. d.
DKG = Deutsche Krebsgesellschaft (German Cancer Society); DGS = Deutsche Gesellschaft für Senologie (German Society of Senology)
L3-GL/ED-BC (2003) = Level-3 Guidelines for the early detection of breast cancer in Germany (2003)
L3-GL/DT-BC (2004) = Interdisciplinary S3 guidelines for the diagnosis and treatment of breast cancer in women (2004)
a Square brackets and italics indicate QIs which were discontinued at the end of 2006; n. d. = no details.
Numbering and names of current QIs and their year of introduction, rationale, quality target and DKG/DGS requirements for years 1 and 3 of 
DKG/DGS certification.
Table 1: Quality indicators (QIs) used in the new, nationwide system for benchmarking breast cancer care in 2007 (Continued)BMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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Proof of concept was also established with regard to defin-
ing a set of, initially, nine rate-based quality indicators
(referred to here as Nos. 1, 2, ex-3, 5, 6, 7.1b, 9, 10 and
11a) based on clinical parameters primarily derived from
the relevant Level-3 guidelines [9,5] and the DKG/DGS
(German Cancer Society/German Society of Senology)
Requirements of Breast Centres (FAB) [3]. These initial
QIs were process indicators selected to serve as surrogate
indicators of outcome quality. As the data accrue over the
coming years, true indicators of outcome quality will be
introduced, the first of which, disease-free survival (DFS),
is in currently preparation.
The successful development of a generic XML-based data
set, i.e. a software-independent data set structure that
readily integrates with any existing tumour documenta-
tion system, enabled standardised, uniform collection
and analysis of QA data on BC care. This has greatly facil-
itated, and continues to facilitate, the participation of a
still growing number of breast centres in this voluntary
benchmarking system designed to evaluate and improve
the quality of BC care.
The generic data set structure ensured that the QA data
were collected consistently across all participating hospi-
Table 2: Changes over time in the quality indicators used for benchmarking in 2007
DKG/DGS requirement
QI No. Quality indicator (QI) Year of introduction 2003 2004 2005 2006 2007 1st year 3rd year
1 Preoperative histological 
confirmation of diagnosis
2003 58% 71% 78% 84% 88% 90%a 90%a
2 Appropriate axillary dissection 2003 85% 85% 80% 83% 88% 85% 95%
[ex-3]b Complete tumour staging data 2003 85% 96% 98% 95% > 95% > 95%
3 Data on safety distance between 
tumour and resection margin
2007 91% 100% 100%
[ex-4]b HER-2/neu assessment 2005 94% 98% > 95% > 95%
4 Specimen radiography 2007 83% > 95% > 95%
5 Hormone receptor assessment 2003 92% 96% 96% 97% 98% 100% 100%
6 Appropriate endocrine therapy in 
hormone receptor-positive 
patients
2003 27% 82% 92% 94% 93% 70% 95%
7.1 Appropriate adjuvant and 
neoadjuvant chemotherapy
2003
7.1a during the current analysis period; age 
≤  70 years
2005 65% 75% 81% 70% 80%
7.1b during the current analysis period; no 
age limit
2003 32% 45% 55% 63% 80% -- --
7.2 Use of appropriate standard 
regimens in chemotherapy
2005
7.2a during the current analysis period; age 
≤  70 years
2006 65% 72% -- --
7.2b during the current analysis period; no 
age limit
2005 57% 60% 69% -- --
8 Percentage of patients in clinical 
trials
2005 8% 7% 7% 10% 20%
9 Appropriate radiotherapy after 
breast-conserving therapy
2003 20% 46% 60% 70% 79% 100%c 100%c
10 Appropriate radiotherapy after 
mastectomy
2003 8% 26% 35% 47% 65% 100%c 100%c
11 Indication for breast-conserving 
therapy
2003
11a at any tumour stage 2003 64% 66% 64% 68% 70% -- --
11b at T1 2005 79% 83% 85% 50% 70%
11c at T2 2006 60% 63% -- --
11d at T3 2006 15% 13% -- --
11e at T4 2006 15% 12% -- --
a requirement for palpable tumours, 70% for nonpalpable tumours
b Square brackets and italics indicate QIs which were discontinued at the end of 2006
c number of radiation treatments to be recorded; exceptions require justification
-- no specified requirement.
Numbering and names, year of introduction, QI values for the 2003–2007 period (mean percentages across all participating institutions) and the 
required percentages for years 1 and 3 of DKG/DGS certification.BMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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tals and all calculations were performed in exactly the
same way using parameter definitions and algorithms laid
down by the data advisory board on the basis of the DKG/
DGS Requirements of Breast Centres (FAB). Accordingly,
the generic XML-based data set ensured the comparability
of results across all participating institutions, thus provid-
ing proof of concept for the feasibility of uniform data col-
lection and data analysis in the context of the present
benchmarking project.
The present study also provided proof of concept for the
feasibility of a benchmarking system based on the QIs
described above in that it proved capable of demonstrat-
ing both QI-specific differences between the anonymised
individual participating institutions in the form of rank-
ings (data not shown) and changes in quality indicators
across the network as a whole, thus indicating improve-
ments in the quality of breast cancer care over the first
five-year period from 2003 to 2007.
The QIs reported here were initially selected with a view,
inter alia, to gauging the quality of care being provided to
patients with primary breast cancer in Germany at the
time in terms of minimum standards and the extent to
which they were being met by each individual participat-
ing centre and across all centres. As evidenced by Table 2
and Figure 3, the project was successful in identifying an
initial set of 9 rate-based QIs, which were reviewed annu-
ally and modified, expanded or discontinued. The first
results for 2003 showed average BC care as provided by
the initial group of 59 participating centres to be reasona-
bly satisfactory, e.g. with regard to axillary dissection (QI
No. 2), complete tumour staging data (QI No. ex-3) and
hormone receptor assessment (QI No. 5), but in need of
improvement in other respects, e.g. endocrine therapy in
hormone receptor-positive patients, radiotherapy after
breast-conserving therapy and radiotherapy after mastec-
tomy (QIs Nos. 6, 9 and 10, respectively).
Performance of quality indicators (QIs) compared to the respective DKG/DGS Requirements of Breast Centres (FAB) during  the 2003–2007 period Figure 3
Performance of quality indicators (QIs) compared to the respective DKG/DGS Requirements of Breast Cen-
tres (FAB) during the 2003–2007 period. QIs Nos.: 1 = Preoperative histological confirmation of diagnosis; 2 = Appropri-
ate axillary dissection; [ex-3] = Complete tumour staging data; 3 = Data on safety distance between tumour and resection 
margin; [ex-4] = HER-2/neu assessment; 4 = Specimen radiography; 5 = Hormone receptor assessment; 6 = Appropriate endo-
crine therapy in hormone receptor-positive patients; 7.1a = Appropriate adjuvant and neoadjuvant chemotherapy during the 
analysis period, age ≤  70 years; 8 = Percentage of patients in clinical trials; 9 = Appropriate radiotherapy after breast-conserving 
therapy; 10 = Appropriate radiotherapy after mastectomy; 11b = Indication for breast-conserving therapy at T1. QI No. 1 (Pre-
operative histological confirmation of diagnosis) was compared against the stricter DKG/DGS requirement of 90% (for palpable 
tumours as opposed to 70% for nonpalpable tumours) as the benchmark. The benchmarking system does not currently distin-
guish between palpable and nonpalpable tumours. QIs labelled "ex-3" (Complete tumour staging data) and "ex-4" (HER 2/neu 
assessment) were discontinued at the end of 2006 and replaced by QIs "3" (Data on safety distance between tumour and resection 
margin) and "4" (Specimen radiography) in 2007. Relative performance was not defined for QIs 7.1b, 7.2a, 7.2b, 11a and 11.c-e in 
the absence of relevant DKG/DGS requirements.
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The project was also successful in demonstrating that up-
to-date QI results could be calculated and reported to the
participating institutions twice a year, thus enabling them
to react in a timely manner and introduce improvements
in the care of their BC patients. In this way, marked
progress was achieved with regard to preoperative histo-
logical confirmation of diagnosis, endocrine therapy in
hormone receptor-positive patients, radiotherapy after
breast-conserving therapy and radiotherapy after mastec-
tomy (QIs Nos. 1, 6, 9 and 10, respectively). Overall,
moderate to marked improvements were achieved for the
vast majority of QIs during the 2003–2007 period. The
most notable exception was the percentage of patients in
clinical trials (QI No. 8), which failed to achieve the DKG/
DGS benchmark value (i.e. the 3rd-year FAB requirement)
of 20% throughout the study period.
Initial high levels of QI performance (QIs Nos. 2, ex-3 and
5) compared to the relevant DKG/DGS benchmarks, and
increases in the performance of most QIs over the first 5-
year period strongly suggest that the quality of BC care in
Germany has improved considerably since 2003. How-
ever, it is clear from Figure 3 that there is still scope for
improvement, particularly with regard to QIs Nos. 2, 3,
and 4 and even more so, Nos. 8, 9 and 10.
During the study period, the initial set of nine QIs was
successively expanded as of 2005 to include new indica-
tors (e.g. No. 8 (2005), 3 and 4 (2007)) and subindicators
(e.g. 7.1a (2005), 7.2b (2005) and 7.2a (2006)). Con-
versely, two QIs (ex-3 (complete tumour staging data) and
ex-4 (HER 2/neu assessment)) were abandoned at the end
of 2006, because they were no longer considered to pos-
sess sufficient discriminatory power to indicate differ-
ences in quality. In addition, the criteria for including
patients in, or excluding them from, the QI calculations
were stated more precisely in several cases. These and
other alterations and revisions demonstrate the flexibility
and adaptability of the benchmarking system we describe.
A major advantage of the newly implemented bench-
marking system is that it permits the collection of longi-
tudinal data over any desired period of time. This will
enable the introduction of true outcome QIs reflecting the
quality of BC care beyond primary hospital care, includ-
ing such aspects as adjuvant therapies, complications after
discharge, disease-free survival, recurrence rates and mor-
tality rates in the near future.
An electronic network is currently being set up in Ger-
many with the aim to establish a comprehensive, nation-
wide quality management system comprising all breast
centres, specialist practices and practising oncologists.
This intersectoral network will utilise the generic XML-
based data set discussed above to enable external, docu-
mentation system-independent collection of all diagnos-
tic, treatment and follow-up data for all breast cancer
patients, especially the follow-up data from the specialists
in private practice.
The participation of two Swiss hospitals in the reported
benchmarking programme strongly suggests that it can
also be implemented in countries other than Germany.
There may, however, be limitations to transferability due
to e.g. potential differences in professional culture, clini-
cal practice or health care system, as recently demon-
strated by Marshall et al. [21] in an analysis of 174 QIs
covering 18 non-cancer conditions with the highest con-
sultation rates in general practice in the United States
compared with the United Kingdom.
Based on the positive experience with benchmarking the
quality of BC care reported here, analogous uniform XML-
based data sets have recently been developed in Germany
for other cancers. In particular, the new benchmarking
system has been adapted for measuring the quality of care
provided to patients with colon or prostate cancer. This
has resulted in the establishment of other site-specific
multidisciplinary cancer centres (for colon and prostate
cancer, to begin with) under the auspices of the German
Cancer Society in collaboration with the German Oncol-
ogy Centre (DOC).
Conclusion
The results from the first five years of the present study
provide proof of concept for the feasibility of a novel, vol-
untary, nationwide system for benchmarking the quality
of BC care based on collaboration between a network of
specialist breast centres and an independent external pro-
vider of scientific data collection and data analysis serv-
ices. The study also provides proof of concept regarding
the uniform collection and analysis of the relevant QA
data by means of a new, purpose-designed, generic XML-
based data set that integrates with any existing tumour
documentation software; the definition of clinically based
indicators of the quality of BC care; and the practicability
of using the quality indicators to measure both within-
network differences in quality (ranking), performance
compared to defined target values (benchmarking) and
changes in the quality of care over time.
The collected data are valid due to the checks performed
during the twice-yearly monitoring visits. The QIs identi-
fied and reviewed in the context of the annual partici-
pants' meetings are sufficiently discriminatory to indicate
both differences in quality among the participating insti-
tutions and changes in quality which occurred over the
first five-year period, 2003–2007. The current QIs can be
considered useful surrogate parameters for long-term out-
come quality, which are expected to become available as
the data accrue over the second five-year period.BMC Cancer 2008, 8:358 http://www.biomedcentral.com/1471-2407/8/358
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After five years, more than 60% of the estimated annual
total of 50,000 new cases of breast cancer in Germany can
be said to be diagnosed, treated and followed up at one of
the now 220 specialist hospitals and breast centres partic-
ipating in the nationwide system for benchmarking the
quality of breast cancer care.
Overall, the new, nationwide benchmarking system has
proved a clinically oriented, practical, flexible, adaptable
and extensible tool for measuring and improving the
quality of breast cancer care during the 2003–2007 study
period.
Finally, with two breast centres in Switzerland joining the
new benchmarking system in 2006, it has been shown
that the collaborative benchmarking network is not per se
limited to Germany but can be extended to the suprana-
tional level.
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